Public health notice: Outbreak of Salmonella infections linked to various brands of salami and cacciatore products Français
This outbreak investigation is ongoing. The public health notice will be updated as the investigation evolves.
OTTAWA, ON, July 19, 2025 /CNW/ -
At a glance
Do not consume, use, sell, serve or distribute recalled salami and cacciatore products. For details on recalled product brand names and lot codes, please consult the Recalls and Safety Alerts website. Over 65 products have been recalled.
These products may have been used in prepared products like sandwiches or sold at deli counters.
Recalled food
Recall warnings have been issued for various salami and cacciatore products, including products from brands:
Bona
Cosmo's Smoked Meats
Imperial Meats
Longos
Luc's European Meats Cheese & Eats
Marini Salumi
Naturissimo
P&E Foods
Rea
Speziale Fine Foods
Superior Meats
T.J. Meats
Vince's Cured Meats Corp.
These products were distributed to:
Grocery stores
Specialty markets
Restaurants and cafés, delis, and butcher shops
These products may have been used and sold in prepared products like sandwiches or at deli counters. These warnings were triggered by findings from the food safety investigation.
For more information on the recalled products, including all product names, descriptions and lot codes, please consult the CFIA's notices on the Recalls and Safety Alerts website.
How to protect your health
Salmonellosis is a foodborne bacterial illness that can affect anyone exposed to a contaminated food product, including the recalled product.
People who are infected with Salmonella bacteria can spread Salmonella to other people several days to several weeks after they have become infected, even if they don't have symptoms.
The following advice applies to individuals, as well as retailers, distributors and food service establishments such as specialty markets, delis, and cafes across Canada:
Check to see if you have the recalled products in your home or establishment by looking for the specific product name and size, UPC and codes in the recall alerts.
Do not consume, serve, use, sell or distribute recalled products or any product made with them.
Throw out or return recalled products to the location where they were purchased. Consumers or establishments who are unsure if they have purchased the recalled products are advised to contact their retailer or supplier where the products were purchased.
Consumers who have purchased a prepared sandwich or meal and are unsure if it contains recalled products are advised to contact the retailer where the item was purchased.
Do not cook food for other people if you've been diagnosed with a Salmonella infection or any other gastrointestinal illness.
Contact your health care provider if you think you're experiencing symptoms of Salmonella.
Most people who become ill from a Salmonella infection will recover fully after a few days without treatment, but it can also cause severe illness and hospitalization.
The Salmonella strain associated with this outbreak investigation is multi drug-resistant, which means it's resistant to certain antibiotics (streptomycin, kanamycin, ampicillin, and sulfisoxazole). Other antibiotics are available to treat illnesses associated with this outbreak strain, if antibiotic treatment is considered necessary.
Those at higher risk for serious illness include:
Symptoms
Salmonellosis has a wide range of symptoms. You may not get sick at all. However, if you do get sick, symptoms usually start within 6 to 72 hours after exposure.
You may experience:
chills
a fever
nausea
diarrhea
vomiting
stomach cramps
a sudden headache
Most symptoms end within 4 to 7 days.
While most people recover completely on their own, some people may have a more serious illness that:
requires hospital care
may lead to long-lasting health effects or death
Salmonellosis (Salmonella)
Food safety for vulnerable populations
Investigation summary
There are 87 laboratory-confirmed cases of Salmonella I 4,[5],12:i:- illness linked to this outbreak in:
British Columbia (1)
Alberta (68)
Manitoba (1)
Ontario (17)
The illness reported in British Columbia is related to travel to Alberta. People became sick between mid-April and late-June 2025. Of the cases reported, nine people have been hospitalized and there have been no deaths. Many people who became sick reported eating salami in prepared sandwiches or purchased from deli counters where the recalled products were served.
People who became sick are between 1 and over 100 years of age.
More recent illnesses may continue to be reported in the outbreak because there is a period between when a person becomes ill and when the illness is reported to public health officials. For this outbreak, the illness reporting period is between 11 and 45 days.
This outbreak may not be limited to the provinces with known illnesses. The recalled products were distributed to:
Alberta
British Columbia
Saskatchewan
Manitoba
Ontario
Quebec
For more details on distribution please consult CFIA's notices on the .
SOURCE Public Health Agency of Canada
Contact us: Public Health Agency of Canada, Media Relations, Telephone: 613-957-2983, Email: [email protected]; Public inquiries, Telephone : 1-866-225-0709 (toll-free), Email: [email protected]

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
6 minutes ago
- Cision Canada
NOTICE TO THE MEDIA - Government of Canada to make an announcement to support access to health services for Francophone minority communities Français
MONCTON, NB, July 21, 2025 /CNW/ - The Honourable Marjorie Michel, Minister of Health, accompanied by the Honourable Ginette Petitpas Taylor, Member of Parliament for Moncton—Dieppe, will make an important announcement to support access to health services in French for Francophone communities. There will be a media availability immediately following the announcement. Date July 22, 2025 Time 10:30 (ADT) Location The event will be held in-person at: Université de Moncton Moncton Campus Léopold-Taillon Pavilion, room 136 18 Antonine-Maillet avenue Moncton, New Brunswick E1A -3E9 Media may also join by Zoom: Passcode: 009354 Please indicate your name (first and last) and media outlet when joining the event. X: @GovCanHealth Facebook: Healthy Canadians SOURCE Health Canada (HC)


Cision Canada
2 hours ago
- Cision Canada
Health Canada Approves KEYTRUDA® for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT)¹ Français
KIRKLAND, QC, July 21, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. 1,2 The approval is based on data from the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, which demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) in patients randomized to KEYTRUDA ® in combination with CRT compared with patients randomized to placebo plus CRT. 3 "The approval of KN-A18 is an important addition to the treatment of gynecological cancers, as it has demonstrated a statistically significant improvement in overall survival and progression-free survival in patients with FIGO 2014 Stage III-IVa," stated Shannon Salvador, Gynecologic Oncologist at the Jewish General Hospital and President of the Society of Gynecologic Oncology of Canada. 4"This recent approval adds another therapeutic option for patients in an important disease space." "This approval marks a pivotal moment for patients, as it represents the first indication in Canada for KEYTRUDA ® in combination with chemoradiotherapy," said André Galarneau, PhD, Executive Director & Vice President, Oncology Business Unit at Merck Canada. "Reaffirming our commitment to cervical cancer, we are eager to continue expanding treatment options for patients impacted by this disease." 5 About KEYNOTE-A18 / ENGOT-cx11/GOG-3047 KEYNOTE-A18 is a multicenter, randomized, double-blind, placebo-controlled phase III trial ( NCT04221945). 2 The trial investigated the efficacy of pembrolizumab in combination with CRT (cisplatin and external beam radiation therapy [EBRT] followed by brachytherapy [BT]) for the treatment of patients with locally advanced cervical cancer. 1 The trial enrolled 1,060 newly diagnosed patients with locally advanced squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix defined as FIGO 2014 stage IB2 to IIB with positive lymph nodes or stage III to IVA regardless of nodal status. 3 There were 599 patients with FIGO 2014 Stage III-IVA. Randomization was stratified by planned type of EBRT (Intensity modulated radiation therapy [IMRT] or volumetric modulated arc therapy [VMAT] vs. non IMRT and non VMAT), stage at screening of cervical cancer (FIGO 2014 Stage IB2 IIB vs. FIGO 2014 Stage III-IVA), and planned total radiotherapy dose (EBRT + brachytherapy dose of <70 Gy vs. ≥70 Gy as per equivalent dose [EQD2]). 1 Patients were randomized (1:1) to one of two treatment arms: Pembrolizumab 200 mg IV every 3 weeks (5 cycles) concurrent with cisplatin 40 mg/m2 IV weekly (5 cycles, an optional sixth infusion could be administered per local practice) and radiotherapy (EBRT followed by BT), followed by pembrolizumab 400 mg IV every 6 weeks (15 cycles). 1,3 Placebo IV every 3 weeks (5 cycles) concurrent with cisplatin 40 mg/m2 IV weekly (5 cycles, an optional sixth infusion could be administered per local practice), and radiotherapy (EBRT followed by BT), followed by placebo IV every 6 weeks (15 cycles). 1,3 Treatment continued until RECIST (Response Evaluation Criteria in Solid Tumors) v1.1-defined progression of disease as determined by investigator or unacceptable toxicity. 1 Assessment of tumour status was performed every 12 weeks from completion of CRT for the first two years, followed by every 24 weeks in year 3, and then annually. The major efficacy outcome measures were PFS as assessed by investigator according to RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or histopathologic confirmation, and OS. 1 The trial demonstrated statistically significant improvements in both PFS (HR (Hazard Ratio) 0.70; 95% CI (confidence interval): 0.55–0.89; p = 0.002) and OS (HR 0.67; 95% CI: 0.50–0.90; p = 0.004) in the overall population. In an exploratory subgroup analysis for the 459 patients (43%) with FIGO 2014 Stage IB2–IIB disease, the PFS and OS HR estimates were 0.91 (95% CI: 0.63–1.32) and 0.89 (95% CI: 0.55–1.44), respectively, suggesting that the improvements in PFS and OS observed in the overall population were primarily driven by the later-stage subgroup of patients with FIGO 2014 Stage III–IVA disease. The efficacy results in the exploratory subgroup analysis of 599 patients with FIGO 2014 Stage III-IVA disease showed that pembrolizumab plus CRT demonstrated improvements in PFS (Hazard Ratio (HR) 0.59; 95% CI 0.43, 0.81) and OS (HR 0.58; 95% CI 0.40, 0.85) in the overall population. 1 For the FIGO 2014 Stage III-IVA population, the most common treatment-related adverse events (reported in at least 20% of patients) were anemia, nausea, diarrhea, white blood cell count decreased, neutrophil count decreased, vomiting, platelet count decreased, and hypothyroidism. 6 For complete information, refer to the KEYTRUDA ® product monograph. About cervical cancer Cervical cancer forms in the cells lining the cervix, which is the lower part of the uterus. 7 Despite concerted efforts in screening and prevention across Canada, cervical cancer has become the fastest growing cancer type in females. 8,9 In 2024 alone, it was estimated that there were approximately 1,600 women diagnosed with cervical cancer and an estimated 400 deaths as a result of the disease. 10 About KEYTRUDA ® KEYTRUDA ® is an anti-programmed death receptor-1 (anti-PD-1) therapy that works by helping increase the ability of the body's immune system to help detect and fight tumour cells. KEYTRUDA ® is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumour cells and healthy cells. 11,12,13 KEYTRUDA ® was first approved in Canada in 2015 and currently has indications in several disease areas, including advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, cervical cancer, esophageal cancer, triple-negative breast cancer, melanoma, and head and neck squamous cell carcinoma. 14 About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information about our operations in Canada, visit and connect with us on LinkedIn @MerckCanada. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( ® Merck Sharp & Dohme LLC. Used under license. © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. CA-NON-04142 1 KEYTRUDA ® Product Monograph, page 285-286. 2 3 The ASCO Post. KEYNOTE-A18: Overall Survival in Cervical Cancer Improved by Pembrolizumab Plus Chemoradiotherapy. 4 Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial, page 1329. 5 6 KEYTRUDA ® Product Monograph, page 146. 7 Canadian Cancer Society. What is cervical cancer? 8 Canadian Cancer Statistics 2023, page 22. 9 Canadian Cancer Statistics 2023, page 80. 10 Canadian Cancer Society. Cervical cancer statistics. 11 KEYTRUDA ® Product Monograph, page 300. 12 KEYTRUDA ® Product Monograph, page 188. 13 KEYTRUDA ® Product Monograph, page 192. 14 KEYTRUDA ® Product Monograph, pages 1-3. Media Contacts: Merck Canada Media Relations 1-833-906-3725 [email protected]


Cision Canada
4 hours ago
- Cision Canada
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias Français
AUSTIN, Texas, July 21, 2025 /CNW/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to implant an FDA-approved novel leadless system that provides cardiac resynchronization therapy to patients with heart failure. Cardiac resynchronization therapy improves the timing of the heart's contractions, helping to restore the normal rhythm of the heartbeat. The first procedure was recently performed by Robert Canby, M.D., cardiac electrophysiologist at TCAI. "This technology marks a significant advancement in how we care for patients with heart rhythm disorders—particularly those who previously had few viable cardiac resynchronization therapy treatment options," said Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI. "At the Texas Cardiac Arrhythmia Institute, our commitment is to bring the most advanced, evidence-based therapies to patients worldwide, and as a result of Dr. Canby's leadership, we successfully delivered on that promise." The system is the first-ever to stimulate the heart muscle electrically via a small, leadless device—about the size of a grain of rice—that is implanted inside tissue of the left ventricle, the heart's primary pumping chamber. The device converts ultrasound energy into electrical pulses, restoring the heart's normal rhythm and pumping efficiency. Traditional cardiac resynchronization therapies involve leads—thin and soft insulated wires about the size of a spaghetti noodle. This left ventricular endocardial pacing device provides a direct approach, which enables more flexible placement and expands access to those who were previously considered untreatable. TCAI is a state-of-the-art Electrophysiology Center that includes six labs equipped with advanced technology where a group of esteemed cardiac electrophysiologists—led by Dr. Natale, a world-renowned expert in the field—perform a high volume of the most complex electrophysiology procedures.